US Stock MarketDetailed Quotes
APVO Aptevo Therapeutics
- 0.613
- -0.154-20.10%
Trading Jun 17 11:03 ET
2.50MMarket Cap-6P/E (TTM)
0.680High0.605Low271.63KVolume0.660Open0.768Pre Close173.84KTurnover6.67%Turnover RatioLossP/E (Static)4.08MShares80.96052wk High0.41P/B2.50MFloat Cap0.60552wk Low--Dividend TTM4.07MShs Float3911.600Historical High--Div YieldTTM9.74%Amplitude0.605Historical Low0.639Avg Price1Lot Size
Aptevo Therapeutics Stock Forum
Sign in to post a comment
This month has been interesting. I bought $Aptevo Therapeutics(APVO.US$ at 0.69 and sold near 1.20 making close to 100% in less than one week. I was also looking at $Fisker(FSRN.US$ shortly after which had experienced a 150% rise recently, although I didn’t end up buying that unfortunetly. Right now I’m currently looking at $FARFETCH LTD(FTCHF.US$ as I believe that is dramatically undervalued compared to both its fundamental data and fair market value. It has relatively s...
5
1
$Aptevo Therapeutics(APVO.US$ .. still drop..no chance to raise next to few months
$Aptevo Therapeutics(APVO.US$ Yes this is pretty heavily shorted! But DAMN! Talk about a offering that has done some serious damage! Sheesh! Its gotta be the addition of the terrible CPI numbers that caused maybe like zero buy pressure at all that added to the massive drop! I mean as far as offerings/dilution goes. This was just a baby offering! Well i guess if you’re already in and at a pretty hi price? If you really like it? Its a place to avera...
3
3
$Aptevo Therapeutics(APVO.US$
NEWS
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
NEWS
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4
$Aptevo Therapeutics(APVO.US$ Aptevo Therapeutics Announces Advancements In Clinical Programs And One Preclinical Program
Benzinga· 1 min ago
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for greater clinical benefit in the ALG.APV-527 clinical trial
Cohort 5 dosing imminent, trial more than 50% enrolled
APVO436 Phase 1b/2 dose ...
Benzinga· 1 min ago
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for greater clinical benefit in the ALG.APV-527 clinical trial
Cohort 5 dosing imminent, trial more than 50% enrolled
APVO436 Phase 1b/2 dose ...
2
4
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Ray Sh : Mr. I am familiar with your kind. Show me screen shot of your buying and selling APVO stock you did with exact date of buy and sell.